Emerald is tackling one of preventive healthcare’s core problems: fragmented health data that makes early intervention difficult. Health information is spread across portals, wearables, PDFs and apps, meaning critical biomarkers can be missed until conditions become serious. The company is positioning itself as a single, continuous health record designed to support earlier, clinically meaningful action.
Emerald combines aggregated health data with human-led care. Each member is paired with a dedicated GP who can review results, diagnose where appropriate, prescribe treatment and guide next steps. This clinical layer sits alongside an intuitive dashboard that helps users understand and track results over time, starting with Emerald’s Baseline blood test covering more than 115 biomarkers and available at over 50 locations across the UK.
The company has raised £1.5m in pre-seed funding, led by Boost Capital Partners, with participation from Mark Fountain and Granatus Ventures, alongside angel investors. The funding brings Emerald’s total pre-seed capital to £1.5m and will support UK expansion and the launch of proprietary coaching protocols in early 2026.
Emerald operates a hybrid model that pairs doctors with AI tools for ongoing monitoring and insight generation. The aim is to combine the scalability of AI with clinical oversight, addressing what the company describes as healthcare’s last mile problem, where insights exist but action is delayed or unclear.
Alongside the funding, Emerald has secured registration with the Care Quality Commission, enabling it to operate as a regulated medical provider. This allows the company to move beyond data interpretation into diagnosis, prescribing and delivery of personalised care plans, positioning Emerald as an active participant in preventive healthcare rather than a passive data platform.
